^
Association details:
| Biomarker: | NPM1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | NSC348884 (Nucleophosmin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1
Excerpt:
...treatment with NSC348884 induced apoptosis of cultured and primary AML with Mt NPM1 but not those AML cells that coexpressed FLT3-ITD. NSC348884 also sensitized AML cells with Mt NPM1 to apoptosis induced by ATRA….Collectively, these data indicate that, while the presence of NPM1 mutation sensitizes AML cells to NSC348884 alone or in combination with ATRA...
DOI:
https://dx.doi.org/10.1182%2Fblood-2010-09-309674
